Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106 isolates) at <256 g/ml and molds (including 10 Aspergillus isolates) at <1,024 g/ml. All fungi were inhibited by omiganan at concentrations well below the 1% (10,000 g/ml) clinical formulation, including species with reduced susceptibility to azoles and echinocandins.
Indwelling venous access devices, especially central venous catheters, are a primary source of nosocomial bloodstream infections, accounting for an estimated 250,000 cases annually in the United States (15) . While staphylococci and enterococci produce most bloodstream infections, data from the National Nosocomial Infections Surveillance system and other published sources has consistently shown that approximately 8 to 10% are produced by Candida spp. (1, 14, 15) . Given the importance of fungi as pathogens in compromised hosts and difficulty in medical management of these infections, prevention of their occurrence can be expected to have a significant impact on overall patient morbidity and mortality and related health care expenditures (1, 4, 5, 16) . The emergence of resistance among fungal pathogens, either appearing de novo or through selection of species with intrinsic resistance mechanisms (e.g., fluconazole resistance in Candida krusei), further confounds this problem and poses special challenges in patient management (3, 11) .
Prevention of local catheter site infections by both bacterial and fungal pathogens is an important component in controlling nosocomial bloodstream infections and improving patient outcomes (15, 19) . Efforts to decrease infection rates have included education on proper catheter insertion techniques and care, use of sterile barrier precautions, and appropriate skin decontamination given many such infections follow from invasion of the transcutaneous catheter tract (15) . The usual skin decontamination protocols have utilized povidone-iodine, isopropyl alcohol, and/or chlorhexidine gluconate, including the use of a chlorhexidine-impregnated dressing (7) . The recent description of human antimicrobial peptides such as defensins and cathelicidins as possible effector molecules in prevention of infection is another novel therapeutic approach based upon the antimicrobial properties of naturally occurring compounds found in leukocytes and epithelial secretions of vertebrates (8) .
One such agent is omiganan, a rapidly bactericidal and fungicidal cationic peptide analog of indolicidin that is known to significantly reduce normal skin flora counts following topical applications (18) . This agent is being developed as a topical Candida spp. antimicrobial agent and is currently in a phase III U.S. and European clinical trial for prevention of catheter-associated infections and in preclinical development for other indications (8-10, 17, 18) . The purpose of this study was to update and expand the analysis of omiganan activity against prevalent fungal pathogens, to better characterize the compound's breadth of spectrum and potency against species commonly encountered in catheter colonization and catheter-associated bloodstream infections, and also to establish the level of activity against prevalent mold species. ( Broth microdilution MIC testing was performed according to CLSI methods (documents M27-A2, M27-S2, and M38-A; 2002) (6, 12, 13) . Omiganan standard powder was solubilized in sterile distilled water; other agents were handled as recommended by CLSI (12, 13) . Panels were produced by JMI Laboratories (North Liberty, IA) using RPMI-1640 broth supplemented with morpholinepropanesulfonic acid buffer; results were recorded at 48 h as specified, and interpretive criteria, where available, were those published in M27-S2 (12) . Quality control (QC) was performed as recommended in M27-A2 and M38-A (12, 13) using the following QC strains: C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. Omiganan QC ranges utilized were those of Anderegg et al. (2) , and all QC results for omiganan and comparator antifungal agents were within the specified control ranges.
Omiganan inhibited all Candida sp. isolates within a 4-log 2 dilution range (16 to 256 g/ml), being most active against C. tropicalis, C. albicans, and C. krusei (concentration at which 50% or 90% of organisms are inhibited [MIC 50 /MIC 90 ], 32 to 64/32 to 128 g/ml) and least active against C. glabrata and C. parapsilosis (MIC 50/ MIC 90 , 128 to 256/256 g/ml [ Table 1 ]). Similar antifungal activity (MIC 50 , 64 g/ml) was evident against C. krusei with intrinsic resistance to fluconazole (MIC 50 , 32 g/ml) compared with that of C. albicans (MIC 50 , 1 g/ml [ Table 2 ]). While all mold isolates were inhibited by Յ1,024 g/ml of omiganan, MIC 90 s for non-Aspergillus spp. were generally fourfold lower than those for Aspergillus spp. (Tables 1 and 2) .
Among comparator antifungal agents, results were highly variable and species dependent, with C. krusei being the most resistant to all agents except voriconazole ( Table 2) . Only amphotericin B and omiganan (MIC 90 , 1 to 2 and 32 to 256 g/ml, respectively) displayed consistent activity against all yeast and mold species.
In the current clinical gel formulation of 1% gel (topical concentration, 10,000 g/ml), omiganan was active against all commonly isolated yeast and mold pathogens (highest documented MICs, 256 and 1,024 g/ml, respectively) associated with catheter-related or sterile site infection, including those species with intrinsically reduced susceptibilities to other antifungal agents (Table 2) .
This cationic peptide (omiganan) represents a "first-inclass" topical agent that displays broad antifungal and antibacterial coverage of all major pathogens responsible for local catheter site and catheter-associated bloodstream infections; none of the currently marketed topical antimicrobials (mupiro- (12, 13) , ongoing surveillance of fungal pathogens implicated in catheter-associated infections will be an important management tool to anticipate changes in species composition, infection rates, and trends of resistance to the applied topical agents, including omiganan.
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